证券代码：603367 证券简称：辰欣药业 公告编号：2025-061 辰欣药业股份有限公司 关于持股 5%以上股东及其一致行动人权益变动触及 1%刻度的提 示性公告 公司持股 5%以上股东韩延振及其一致行动人江苏辰昕同泰企业管理有限公司保证 向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少√ | | --- | --- | --- | --- | | 权益变动前合计比例 | 6.37% | | | | 权益变动后合计比例 | 5.83% | | | | 本次变动是否违反已作出的承诺、 | 是□ | 否√ | | | 意向、计划 | | | | | 是否触发强制要约收购义务 | 是□ | 否√ | | 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 二、 权益变动触及 1%刻度的基本情况 2025 年 11 月 25 日，公司收到持股 5%以上股东韩延振出具的《大宗交易股 份减持告知函》，获悉其于 2025 年 11 月 24 日以大宗交易 ...

证券代码：603367 证券简称：辰欣药业 公告编号：2025-060 辰欣药业股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 26 日 （星期三） 09:00-10:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadsho w.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 21 日 （星期五）至 11 月 25 日 （星期二）1 6:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过辰欣药业股 份有限公司（以下简称"公司"）邮箱 cxyy@cisenyy.com 进行提问。公司将在说 明会上对投资者普遍关注的问题进行回答。 公司已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投 资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 26 ...

Group 1 - The core point of the news is that Chenxin Pharmaceutical's stock price dropped by 5.13% to 19.59 CNY per share, with a trading volume of 279 million CNY and a turnover rate of 3.08%, resulting in a total market capitalization of 8.869 billion CNY [1] - Chenxin Pharmaceutical, established on November 6, 1998, and listed on September 29, 2017, is primarily engaged in the research, development, and production of chemical drug formulations [1] - The company's main revenue sources are: large-volume infusion (42.66%), small-volume injectables (29.80%), oral solid preparations (13.98%), drops (4.31%), lyophilized powder injections (3.68%), ointments (3.43%), raw materials (1.35%), rinsing agents (0.59%), and others (0.20%) [1] Group 2 - Among the top circulating shareholders of Chenxin Pharmaceutical, Ping An Fund's Ping An Medical Health Mixed A (003032) entered the top ten in the third quarter, holding 3.8777 million shares, accounting for 0.86% of the circulating shares, with an estimated floating loss of approximately 4.1104 million CNY [2] - Ping An Medical Health Mixed A (003032) was established on November 24, 2017, with a latest scale of 2.028 billion CNY, achieving a year-to-date return of 63.9% and ranking 315 out of 8138 in its category [2] - The fund manager of Ping An Medical Health Mixed A is Zhou Sicong, who has a cumulative tenure of 11 years and 314 days, with the fund's total asset size at 5.51 billion CNY and a best return of 104.39% during his tenure [3]

4、注册资本：1427.766万元整 5、成立日期：2022年11月17日 6、法定代表人：韩延振 7、住所：东台市高新技术产业开发区创业大厦623-10室 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 辰欣药业股份有限公司（以下简称"公司"或"辰欣药业"）近日收到持股5%以上股东韩延振的一致行动 人南京辰昕同泰创业投资有限公司的告知函，其公司名称已由"南京辰昕同泰创业投资有限公司"变更 为"江苏辰昕同泰企业管理有限公司"（以下简称"江苏辰昕"）,注册地址和经营范围均进行了变更。江 苏辰昕目前已办理完毕前述工商变更手续，并领取了东台市政务管理办公室颁发的《营业执照》，变更 后的《营业执照》主要内容如下： 1、名称：江苏辰昕同泰企业管理有限公司 2、统一社会信用代码：91450500MAA7RJX51G 3、类型：有限责任公司（自然人投资或控股） 江苏辰昕本次名称及注册地址、经营范围变更后，仍系公司持股5%以上股东韩延振的一致行动人。江 苏辰昕本次工商登记信息变更不涉及其持有公司股份数量及比例的变动，对公司治理及经营活动不构成 ...

证券代码：603367 证券简称：辰欣药业 公告编号：2025-059 辰欣药业股份有限公司 关于持股5%以上股东的一致行动人变更名称、 辰欣药业股份有限公司 注册地址和经营范围的公告 董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 2025年11月17日 辰欣药业股份有限公司（以下简称"公司"或"辰欣药业"）近日收到持股5%以上股东韩延振的一致行动 人南京辰昕同泰创业投资有限公司的告知函，其公司名称已由"南京辰昕同泰创业投资有限公司"变更 为"江苏辰昕同泰企业管理有限公司"（以下简称"江苏辰昕"）, 注册地址和经营范围均进行了变更。江 苏辰昕目前已办理完毕前述工商变更手续，并领取了东台市政务管理办公室颁发的《营业执照》，变更 后的《营业执照》主要内容如下： 1、名称：江苏辰昕同泰企业管理有限公司 2、统一社会信用代码：91450500MAA7RJX51G 3、类型：有限责任公司（自然人投资或控股） 4、注册资本：1427.766万元整 5、成立日期：2022年11月17日 6、法定代表人：韩延振 7、住所：东台市高新 ...

辰欣药业股份有限公司（以下简称"公司"或"辰欣药业"）近日收到 持股 5%以上股东韩延振的一致行动人南京辰昕同泰创业投资有限公司的告 知函，其公司名称已由"南京辰昕同泰创业投资有限公司"变更为"江苏辰 昕同泰企业管理有限公司"（以下简称"江苏辰昕"）, 注册地址和经营范 围均进行了变更。江苏辰昕目前已办理完毕前述工商变更手续，并领取了东 台市政务管理办公室颁发的《营业执照》，变更后的《营业执照》主要内容 如下： 证券代码：603367 证券简称：辰欣药业 公告编号：2025-059 辰欣药业股份有限公司 关于持股 5%以上股东的一致行动人变更名称、注册地址和经营 范围的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1、名称：江苏辰昕同泰企业管理有限公司 2、统一社会信用代码：91450500MAA7RJX51G 3、类型：有限责任公司（自然人投资或控股） 4、注册资本：1427.766 万元整 5、成立日期：2022 年 11 月 17 日 6、法定代表人：韩延振 7、住所：东台市高新技术产业开发区创业大厦 623-1 ...

辰欣药业公告称，近日收到持股5%以上股东韩延振的一致行动人南京辰昕同泰创业投资有限公司告知 函，其名称变更为江苏辰昕同泰企业管理有限公司，注册地址和经营范围也进行了变更，已办理完工商 变更手续。该公司注册资本1427.766万元，法定代表人为韩延振。此次变更不涉及该公司持有公司股份 数量及比例变动，对公司治理及经营活动无影响。 ...

Core Viewpoint - The A-share market has seen a significant rise in flu-related stocks due to a noticeable increase in flu activity across China, with most provinces entering the flu epidemic period [1] Group 1: Stock Performance - Hendi Pharmaceutical has increased by over 14%, while Hualan Biological has risen by 11% [1] - Other notable performers include Peking University Pharmaceutical with a 10% increase, and Jinshi Yao with a rise of over 7% [1] - Several companies, including Teva Pharmaceutical, Erkang Pharmaceutical, and others, have also shown gains of over 5% [1] Group 2: Market Context - Recent data from the China CDC indicates that flu virus cases have surpassed other respiratory viruses, marking a significant shift in the current flu season [1] - Since mid-October, sales of related medications, such as Oseltamivir, have increased, with production running continuously [1]

Core Viewpoint - Recent data indicates a significant rise in influenza activity in China, with a notable increase in patients visiting hospitals for treatment, prompting the need for early antiviral therapy and consideration of various factors in drug selection [1][2][3] Group 1: Influenza Activity - The latest report from the Chinese Center for Disease Control and Prevention shows a marked increase in influenza activity, particularly in southern provinces, with the percentage of influenza-like illness (ILI) cases reported at 4.6%, up from 4.1% the previous week [2] - Northern provinces reported an ILI percentage of 5.1%, significantly higher than the previous week's 3.7% and above levels from 2022, 2023, and 2024 [2] - A total of 347 influenza-like illness outbreaks were reported nationwide, with 245 cases identified as A(H3N2) [2] Group 2: Treatment and Drug Approval - The increase in influenza cases has led to a rise in hospital visits, particularly in pediatric departments, with doctors recommending early antiviral treatment within 48 hours of symptom onset [4] - Oseltamivir remains the preferred antiviral treatment, especially for children and immunocompromised patients, with over 120 approvals for related products from various companies [4][5] - The market for oseltamivir is dominated by Dongyangguang Pharmaceutical, holding over 70% market share in the past three years [4] Group 3: New Drug Developments - Several new RNA polymerase inhibitors have been approved in China, with the year 2025 being referred to as the "Year of Domestic Influenza New Drugs" [1][6] - Roche's Marbofloxacin has seen a significant increase in demand, with supply pressures leading to local production initiatives [6][7] - Other domestic companies, such as Qingfeng Pharmaceutical and Zhongsheng Pharmaceutical, have also launched new antiviral drugs, contributing to a broader range of treatment options for influenza [7][8] Group 4: Market Dynamics - The price of Marbofloxacin ranges from 195 to 234 yuan per pack, with no adjustments made by Roche despite increased demand [7] - Companies like Haizheng Pharmaceutical have reported a significant rise in demand for their antiviral products, with ongoing supply guarantees in place [8][9] - The market is seeing increased competition as more domestic firms enter the RNA polymerase inhibitor space, with several products currently in clinical trials or awaiting approval [9]

Core Viewpoint - Chenxin Pharmaceutical is a well-established chemical drug manufacturer in China, with a strong focus on research and development, and has been listed on the Shanghai Stock Exchange since 2017 [1] Group 1: Business Performance - In Q3 2025, Chenxin Pharmaceutical achieved a revenue of 2.584 billion yuan, ranking 27th among 110 companies in the industry, with the industry leader, East China Pharmaceutical, generating 32.664 billion yuan [2] - The company's net profit for the same period was 385 million yuan, placing it 21st in the industry, while the top performer, Hengrui Medicine, reported a net profit of 5.76 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Chenxin Pharmaceutical's debt-to-asset ratio was 18.72%, down from 21.48% year-on-year, significantly lower than the industry average of 35.26%, indicating strong solvency [3] - The company's gross profit margin stood at 55.08%, slightly below the industry average of 57.17%, reflecting a competitive profitability position [3] Group 3: Executive Compensation - The chairman and general manager, Du Zhenxin, received a salary of 1.1628 million yuan in 2024, an increase of 191,000 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 14.38% to 30,800, while the average number of circulating A-shares held per shareholder increased by 16.79% to 14,700 [5]